The DOI matches its Crossref record; 310 of the 310 references it cites were found in a registry or an index.
Regulatory T cells in the treatment of disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Autoimmunity and organ damage in systemic lupus erythematosus
Tsokos, G. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0677-6 · Cited by 580
Self-citationEffects of Omega-3 Fatty Acids on Immune Cells
Gutiérrez, S., Svahn, S. L., & Johansson, M. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205028 · Cited by 525
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
Zhou, C., Li, X., Wang, C., & Zhang, J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08883-0 · Cited by 393
The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications
Leonard, W. J., Lin, J.-X., & O'Shea, J. J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.028 · Cited by 383
Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China
Tan, M., Liu, Y., Zhou, R., Deng, X., Li, F., Liang, K., & Shi, Y. (2020) · Immunology · doi:10.1111/imm.13223 · Cited by 377
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
Type I interferon-mediated tumor immunity and its role in immunotherapy
Yu, R., Zhu, B., & Chen, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04219-z · Cited by 309
Doloff, J. C., Veiseh, O., de Mezerville, R., Sforza, M., Perry, T. A., Haupt, J., Jamiel, M., Chambers, C., Nash, A., Aghlara-Fotovat, S., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00739-4 · Cited by 302
T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy
Sharabi, A., & Tsokos, G. C. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0356-x · Cited by 290
Self-citationTurning up the heat on non-immunoreactive tumours: opportunities for clinical development
Ochoa de Olza, M., Navarro Rodrigo, B., Zimmermann, S., & Coukos, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30234-5 · Cited by 256
HIF-2α is indispensable for regulatory T cell function
Hsu, T.-S., Lin, Y.-L., Wang, Y.-A., Mo, S.-T., Chi, P.-Y., Lai, A. C.-Y., Pan, H.-Y., Chang, Y.-J., & Lai, M.-Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18731-y · Cited by 126
Negi, N., & Griffin, M. D. (2020) · Stem Cells · doi:10.1002/stem.3151 · Cited by 118
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells
Vidana Gamage, H. E., Albright, S. T., Smith, A. J., Farmer, R., Shahoei, S. H., Wang, Y., Fink, E. C., Jacquin, E., Weisser, E., Bautista, R. O., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217086 · Cited by 13
Metadata
- Authors
- Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-10-12
- Volume
- 17
- Issue
- 11
- Pages
- 823-844
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2896517179
- Cited by
- 297
- References
- 310
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.